The Global Rivastigmine Transdermal Patches Market was valued at US$ 192.2 million in 2023 and is projected to reach US$ 237.9 million by 2030, at a CAGR of 3.2% during the forecast period. The ...
TOKYO, March 31, 2025 /PRNewswire/ -- Luye Pharma Group today announced that marketing approval for its innovative formulation Rivastigmine Twice Weekly Transdermal Patch has been granted by the ...
The global transdermal patch market, projected to grow from $1.61 billion in 2024 to $2.35 billion by 2029, is expected to reach $18 billion by 2030, expanding at a CAGR of 7.8%. The U.S. leads with a ...
Luye Pharma Group today announced that its subsidiary Luye Pharma Switzerland AG has entered into agreements with Exeltis Pharma México, S.A. de C.V and Exeltis Pharmaceuticals Holding, S.L (Exeltis), ...
AD has become a major public health challenge worldwide. In South Korea, AD cases are constantly growing along with population aging [1][2]. Treating AD is challenging due to conditions such as ...
China’s National Medical Products Administration has approved Sino Biopharmaceutical Ltd.’s rivastigmine transdermal patch to treat mild to moderate Alzheimer’s disease. Developed by Sino Biopharm, ...
BRIDGEWATER, N.J., Jan. 14, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of Exelon ® Patch (Rivastigmine ...
-- Approval based on efficacy and safety demonstrated in long-term study comparing 13.3 mg/24 h to 9.5 mg/24 h in declining mild to moderate Alzheimer's patients EAST HANOVER, N.J. -- The US Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback